CVE-2026-123051: CIPCarbone srl Farmasimplex REV.exe · Use of Hard-coded Credentials
Affects CIPCarbone srl Farmasimplex REV.exeSource CVE Database V5
Not known to be exploited · CVSS 1.2 Low : upgrade to 16.2.0 when convenient.
Data as of 17 Nov 2026, 14:54 UTC
Thin evidence
One scorer or none| CNA (ENISA) | CVSS 4.0 | 1.2 |
|---|
- Patch
- Available – fixed in 16.2.0
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:N/SC:N/SI:N/SA:N/E:UExploitation evidence
Disclosed: evidence found.
CVE published 17 Nov 2026
Detectable: no evidence on record.
No public nuclei template indexed
Weaponized: no evidence on record.
No public exploit code indexed in Metasploit or Exploit-DB
Exploited in the wildExploited: no evidence on record.
Not in CISA KEV and no source reports exploitation
Observed by OffSeq MirageSeen by Mirage: no evidence on record.
No attack traffic recorded by OffSeq Mirage sensors
A missing step is not evidence of safety. Sources: cve.org (opens in a new tab), the Metasploit, Exploit-DB and nuclei-templates index as of 16 Nov 2026.
What to do
Upgrade CIPCarbone srl Farmasimplex REV.exe to 16.2.0.
Affected software
| Product | Affected | Fixed in |
|---|---|---|
| CIPCarbone srlFarmasimplex REV.exe | Affected
| Fixed in
|
AI-suggested
Upgrade Farmasimplex REV.exe to version 16.2.0 or later, where the hard-coded credential issue has been fixed. No additional mitigation is required if the system is updated to this fixed version.
Description
CVE-2026-123051 is a low-severity vulnerability in the Farmasimplex REV.exe module by CIPCarbone srl. The executable contains hard-coded OAuth client credentials used for integration with the IZS platform. An attacker who obtains the executable could extract these credentials and potentially misuse them to access integration resources or manipulate data, depending on the privileges and authentication controls. This issue is fixed in version 16.2.0.